A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment.

ABSTRACT:

Objective

Current type 2 diabetes (T2D) management contraindicates intensive glycemia treatment in patients with high cardiovascular disease (CVD) risk and is partially motivated by evidence of harms in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Heterogeneity in response to intensive glycemia treatment has been observed, suggesting potential benefit for some individuals.

Research design and methods

ACCORD was a randomized controlled trial that investigated whether intensively treating glycemia in individuals with T2D would reduce CVD outcomes. Using a novel approach to cluster HbA_1c trajectories, we identified groups in the intensive glycemia arm with modified CVD risk. Genome-wide analysis and polygenic score (PS) were developed to pred

SUBMITTER: Mariam A 

PROVIDER: S-EPMC8247498 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature